Zhejiang Zhenyuan Share Co Ltd - Asset Resilience Ratio
Zhejiang Zhenyuan Share Co Ltd (000705) has an Asset Resilience Ratio of 5.75% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Zhejiang Zhenyuan Share Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2021)
This chart shows how Zhejiang Zhenyuan Share Co Ltd's Asset Resilience Ratio has changed over time. See Zhejiang Zhenyuan Share Co Ltd (000705) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Zhenyuan Share Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Zhejiang Zhenyuan Share Co Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥170.00 Million | 5.75% |
| Total Liquid Assets | CN¥170.00 Million | 5.75% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Zhenyuan Share Co Ltd maintains only 5.75% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Zhenyuan Share Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Zhenyuan Share Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.09% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 10.03% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
Annual Asset Resilience Ratio for Zhejiang Zhenyuan Share Co Ltd (1997–2021)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Zhenyuan Share Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 7.37% | CN¥220.00 Million ≈ $32.19 Million |
CN¥2.99 Billion ≈ $437.00 Million |
+1.81pp |
| 2020-12-31 | 5.55% | CN¥150.00 Million ≈ $21.95 Million |
CN¥2.70 Billion ≈ $395.28 Million |
-4.10pp |
| 2019-12-31 | 9.66% | CN¥250.00 Million ≈ $36.58 Million |
CN¥2.59 Billion ≈ $378.79 Million |
+8.68pp |
| 2015-12-31 | 0.98% | CN¥19.00 Million ≈ $2.78 Million |
CN¥1.94 Billion ≈ $283.62 Million |
-4.60pp |
| 2000-12-31 | 5.58% | CN¥40.00 Million ≈ $5.85 Million |
CN¥716.33 Million ≈ $104.82 Million |
+3.79pp |
| 1999-12-31 | 1.79% | CN¥10.00 Million ≈ $1.46 Million |
CN¥557.35 Million ≈ $81.56 Million |
-5.45pp |
| 1998-12-31 | 7.24% | CN¥40.00 Million ≈ $5.85 Million |
CN¥552.33 Million ≈ $80.82 Million |
+2.24pp |
| 1997-12-31 | 5.00% | CN¥28.00 Million ≈ $4.10 Million |
CN¥559.86 Million ≈ $81.93 Million |
-- |
About Zhejiang Zhenyuan Share Co Ltd
Zhejiang Zhenyuan Share Co.,Ltd. engages in the manufacture and wholesale of pharmaceutical products in China and internationally. Its products include Chinese herbal medicines and slices, Chinese patent medicines, chemical raw materials, chemical preparations, antibiotics, biochemical drugs, biological products, medical devices, chemical reagents, glass instruments, etc. The company also provide… Read more